Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome

Currow, DC; Abernethy, AP

Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome

Currow, DC

Abernethy, AP

Permalink

Publication Type:: Journal Article
Citation:: Future Oncology, 2014, 10 (5), pp. 789 - 802
Issue Date:: 2014-01-01

Closed Access

	Filename	Description	Size
	out (9).pdf	Published Version	1.84 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Currow, DC https://orcid.org/0000-0003-1988-1250	en_US
dc.contributor.author	Abernethy, AP	en_US
dc.date.issued	2014-01-01	en_US
dc.identifier.citation	Future Oncology, 2014, 10 (5), pp. 789 - 802	en_US
dc.identifier.issn	1479-6694	en_US
dc.identifier.uri	http://hdl.handle.net/10453/118967
dc.description.abstract	Anamorelin hydrochloride is an orally active ghrelin receptor agonist in development by Helsinn, for the treatment of non-small-cell lung cancer (NSCLC) cachexia. In preclinical and clinical studies, the potent affinity of anamorelin for the ghrelin receptor is associated with significant appetite-enhancing activity and resultant improvements in body weight, lean body mass, and handgrip strength compared with placebo. The accompanying stimulatory effects on growth hormone and IGF-1 are not associated with tumor growth, and overall survival in patients with cancer is not compromised. Anamorelin is well tolerated with no dose-limiting toxicities identified to date. The findings of ongoing Phase III studies are needed to confirm the significant potential of anamorelin to treat NSCLC cachexia. © 2014 Future Medicine Ltd.	en_US
dc.relation.ispartof	Future Oncology	en_US
dc.relation.isbasedon	10.2217/fon.14.14	en_US
dc.subject.classification	Oncology & Carcinogenesis	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Carcinoma, Non-Small-Cell Lung	en_US
dc.subject.mesh	Cachexia	en_US
dc.subject.mesh	Anorexia	en_US
dc.subject.mesh	Hydrazines	en_US
dc.subject.mesh	Oligopeptides	en_US
dc.subject.mesh	Receptors, Ghrelin	en_US
dc.title	Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome	en_US
dc.type	Journal Article
utslib.citation.volume	5	en_US
utslib.citation.volume	10	en_US
utslib.for	1112 Oncology and Carcinogenesis	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/IMPACCT
utslib.copyright.status	closed_access
pubs.issue	5	en_US
pubs.publication-status	Published	en_US
pubs.volume	10	en_US

Abstract:

Anamorelin hydrochloride is an orally active ghrelin receptor agonist in development by Helsinn, for the treatment of non-small-cell lung cancer (NSCLC) cachexia. In preclinical and clinical studies, the potent affinity of anamorelin for the ghrelin receptor is associated with significant appetite-enhancing activity and resultant improvements in body weight, lean body mass, and handgrip strength compared with placebo. The accompanying stimulatory effects on growth hormone and IGF-1 are not associated with tumor growth, and overall survival in patients with cancer is not compromised. Anamorelin is well tolerated with no dose-limiting toxicities identified to date. The findings of ongoing Phase III studies are needed to confirm the significant potential of anamorelin to treat NSCLC cachexia. © 2014 Future Medicine Ltd.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/118967